G1 Therapeutics, Inc. provided Financial Guidance for the full year 2023. For the period, the company expects to generate between $50 million and $60 million in COSELA net revenue in 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.09 USD | -3.08% | -9.71% | +34.10% |
05-23 | G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting | CI |
05-22 | Sector Update: Health Care Stocks Lower Premarket Wednesday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.10% | 214M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- GTHX Stock
- News G1 Therapeutics, Inc.
- G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023